AI drug validation startup Polyphron raises $20M seed from Gradient, Quiet, Compound
darian314 · x · 2026-09-17
Polyphron announced a $20M seed round backed by Gradient, Quiet Capital and Compound, as reported by Axios. Founded by Matthew Osman, the startup builds human tissue models and generation technology to validate AI-created drugs, aiming to get new medicines to market faster and more safely.
More from Venture
- Indie Dev's Founder Lifts Leaderboard Hits 101K Impressions After 2-Hour Build — denisyurchak · 2026-11-02
- Post Bridge Loses 20% of Customers Monthly; Founders Workshop the ICP Narrowing Dilemma Live — tibo_maker · 2026-11-02
- Enterprise AI's real game: getting companies to spend far more, not less — inductionheads · 2026-11-02
- Marvell and Lumentum to merge, targeting $550B AI connectivity market — BenBajarin · 2026-11-02
- OpenAI has raised less than half of its $30B target in latest funding round, WSJ reports — pstAsiatech · 2026-11-02
- What 150k-follower Bilibili gaming creators charge: 8,500 yuan per video — ezshine · 2026-11-02